Edwards Lifesciences Corp

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $569.5m
$583.6m +2.48%
$722.2m +23.75%
$1.0b +44.96%
$823.4m -21.35%
$1.5b +82.55%
$1.5b +1.25%
$1.4b -7.85%
$4.2b +197.68%
$1.1b -74.28%
Net Income (Loss) Available to Common Stockholders, Basic $569.5m
$583.6m +2.48%
$722.2m +23.75%
$1.0b +44.96%
$823.4m -21.35%
$1.5b +82.55%
$1.5b +1.25%
$1.4b -7.85%
$4.2b +197.33%
$1.1b -74.35%
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $1.4b $4.2b $1.1b
Net Income (Loss) Attributable to Noncontrolling Interest ($3.0m) ($4.9m) ($4.1m)
Depreciation, Depletion and Amortization $71.2m $81.9m $77.4m $89.3m $107.2m $134.8m $139.6m $144.9m $155.2m $156.6m $165.5m
Depreciation $63.6m $74.1m $74.9m $84.7m $101.8m $127.0m $133.9m $138.9m $137.6m $148.2m $138.9m
Amortization of Intangible Assets $7.6m $7.8m $2.5m $4.6m $5.4m $7.7m $5.7m $6.1m $5.6m $8.4m
Deferred Income Tax Expense (Benefit) ($24.5m) $27.1m ($21.2m) $10.5m ($52.2m) ($44.0m) ($250.9m) ($262.0m) ($162.8m) ($65.8m) $118.3m
Share-based Payment Arrangement, Noncash Expense $56.9m $61.6m $71.0m $81.3m $92.6m $109.3m $126.8m $139.4m $162.3m $158.1m $168.0m
Share-based Payment Arrangement, Expense $56.9m $61.6m $71.0m $81.3m $92.6m $109.3m $126.8m $139.4m $145.6m $157.9m $168.0m
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount $700k
Impairment of Intangible Assets, Finite-lived $0 $4.0m $55.1m $0 $0 $40.0m
Nonoperating Income (Expense) $169.4m $8.7m
Other Nonoperating Income (Expense) ($4.9m) ($8.2m) $4.0m $8.2m $11.5m $12.7m $2.6m $14.4m $68.9m $7.2m
Changes in operating assets and liabilities:
Increase (Decrease) in Inventories $65.6m $124.0m $65.7m $105.4m $120.6m ($19.0m) $213.4m $289.0m $256.1m ($50.7m) ($15.9m)
Inventory Write-down $73.1m $0 $0
Other Operating Income (Expense), Net $0 $0 $300k $67.2m
Net Cash Provided by (Used in) Operating Activities $704.4m
$1.0b +42.06%
$926.8m -7.38%
$1.2b +27.26%
$1.1b -10.61%
$1.7b +64.29%
$1.2b -29.67%
$895.8m -26.47%
$542.3m -39.46%
$1.6b +194.15%
$1.7b +7.84%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $176.1m $168.1m $238.7m $254.4m $407.0m $325.8m $244.6m $253.0m $252.4m $260.2m ($286.7m)
Gain (Loss) on Investments ($51.5m) ($100k) $5.2m $8.3m
Payments to Acquire Businesses, Net of Cash Acquired $0 $192.9m $0 $100.2m ($99.9m)
Payments for (Proceeds from) Other Investing Activities $1.2m ($800k) ($5.2m) $24.0m $12.1m $44.4m $28.8m $12.5m $72.9m $7.4m
Net Cash Provided by (Used in) Investing Activities ($211.7m) ($647.2m) $76.7m ($595.8m) ($531.1m) ($1.7b) $252.3m $173.8m $2.3b ($712.9m) ($912.1m)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $253.5m $994.7m $688.0m $18.9m $16.2m $5.2m $0 $0
Payments for Repurchase of Common Stock $662.3m $763.3m $795.5m $263.3m $625.4m $512.8m $1.7b $879.6m $1.2b $893.4m
Proceeds from (Payments for) Other Financing Activities $4.1m $0 ($300k) ($2.8m) ($1.2m) ($300k) ($3.6m) ($1.0m) ($3.1m) ($3.8m)
Net Cash Provided by (Used in) Financing Activities ($268.5m)
($473.2m) -76.24%
($1.1b) -132.71%
($115.6m) +89.50%
($486.9m) -321.19%
($356.3m) +26.82%
($1.6b) -344.71%
($711.0m) +55.13%
($983.0m) -38.26%
($956.8m) +2.67%
($1.2b) -25.73%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $7.9m ($6.5m) $465.0m $15.8m ($332.8m) ($94.8m) $375.4m $1.9b ($119.3m) $2.9b
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.9m ($6.5m) $1.2b $1.2b $867.4m $772.6m $1.1b $3.1b $2.9b $2.9b
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.9m ($6.5m) ($3.0m) ($20.5m) $13.9m $19.2m $16.8m $38.6m ($44.8m) $14.5m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $77.6m $103.7m $110.4m $79.2m $82.2m $64.8m $83.4m $90.6m $89.2m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $30.1m $19.9m $19.9m $20.2m $19.3m $19.9m $19.6m $20.2m
Income Taxes Paid, Net $490.4m
Additional Financial Items
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net $0 $0 $55.0m $0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment ($1.2m) ($400k)
Foreign Currency Transaction Gain (Loss), before Tax ($500k) ($5.4m) $6.7m $5.9m $12.3m $5.0m ($1.2m) $10.5m $7.1m $700k
Gain (Loss) on Disposition of Business $3.3b $33.9m
Gain (Loss) Related to Litigation Settlement $0
Goodwill $626.1m $1.1b $1.1b $1.2b $1.2b $1.2b $1.2b $1.3b $1.8b $1.8b $303.4m
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent $1.4b $1.1b
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $1.4b $1.1b
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $2.8b $13.4m
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $2.8b $13.4m
Income Tax Expense (Benefit) $168.4m $451.3m $39.2m $119.6m $93.3m $198.9m $245.5m $198.7m $152.1m $216.9m
Insured Event, Gain (Loss) $3.8m $0 $0
Interest Expense Nonoperating $19.8m $20.4m
Investment Income, Interest $10.8m $20.3m $32.0m $32.2m $23.4m $17.4m $35.5m $67.2m $120.3m $168.8m

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.